Alternate test to detect prognostically important genomic abnormalities in CLL.
Fluorescence in situ Hybridization (FISH)
Green (sodium heparin). Also acceptable: Non-diluted bone marrow aspirate collected in a heparinized syringe.
Transport 5 mL whole blood (Min: 2 mL). OR Transfer 3 mL bone marrow to a green (sodium heparin) (Min: 1 mL)
Frozen specimens. Paraffin-embedded specimens. Clotted specimens.
Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable.
Refer to report.
Compliance Statement A: For laboratory developed tests using a manufacturer labeled ASR as the reagent providing the specificity of the assay. Analyte Specific Reagent. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, the FDA has determined that such clearance or approval is not necessary.
Fluorescence in situ Hybridization panel is performed for CLL prognosis-specific genomic abnormalities as follows: ATM deletion, D13S319 deletion, Trisomy 12, TP53 deletion.
A processing fee will be charged if this procedure is canceled at the client's request, after the test has been set up, or if the specimen integrity is inadequate to allow culture growth
If cell pellets or dropped cytogenetic slides are submitted, processing fee will not apply.
This test must be ordered using Oncology test request form #43099 or through your ARUP interface.
88271 x4; 88275 x4; 88291
|Component Test Code*||Component Chart Name||LOINC|
|0092616||Chromosome FISH, CLL Panel||57802-1|
|2002197||EER Chromosome FISH, CLL Panel||11526-1|
- 'Chronic Lymphocytic Leukemia FISH Panel